
Opinion|Videos|May 12, 2025
The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
Panelists discuss how evaluating a renal mass requires considering multiple factors, including patient expectations, comorbidities, life expectancy, tumor characteristics such as size and enhancement patterns, and predictive models to help guide decision-making.
Advertisement
Episodes in this series

Clinical Challenges in Renal Mass Evaluation
Main Discussion Topics:
- Multiple factors influence management decisions, including patient expectations, comorbidities, life expectancy, and tumor characteristics.
- Tumor assessment includes size, growth kinetics, and enhancement characteristics.
- Predictive models help assess patient longevity and tumor behavior.
Key Points for Physicians:
- Comprehensive assessment requires consideration of patient factors and tumor characteristics.
- Enhancement patterns on imaging provide valuable diagnostic information.
- Existing predictive models can help guide clinical decision-making.
Notable Insights:
Decision-making for renal masses requires a multifaceted approach that integrates patient-specific factors with tumor radiographic characteristics.
Clinical Significance:
A systematic approach that considers both patient factors and tumor characteristics leads to more appropriate management decisions for renal masses.
Advertisement
Related to this article

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.

Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement

